OT: Distressing Shift in Pharma Thinking [7:09 pm]
Until now, drug makers have typically defended high prices by noting the cost of developing new medicines. But executives at Genentech and its majority owner, Roche, are now using a separate argument –— citing the inherent value of life-sustaining therapies.
Also known as “your money or your life” pricing.
Later: From the 2/17 NYTimes: Editorial: Price Gouging on Cancer Drugs?